Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.

ABSTRACT:

Objective

To determine whether a non‑platinum chemotherapy doublet improves overall survival (OS) among patients with recurrent/metastatic cervical carcinoma.

Methods

Gynecologic Oncology Group protocol 240 is a phase 3, randomized, open-label, clinical trial that studied the efficacy of paclitaxel 175 mg/m² plus topotecan 0.75 mg/m² days 1-3 (n = 223) vs cisplatin 50 mg/m² plus paclitaxel 135 or 175 mg/m² (n = 229), in 452 patients with recurrent/metastatic cervical cancer. Each chemotherapy doublet was also studied with and without bevacizumab (15 mg/kg). Cycles were repeated every 21 days until progression, unacceptable toxicity, or complete response. The primary endpoints were OS and the frequency and severity of adverse effect

SUBMITTER: Tewari KS 

PROVIDER: S-EPMC10286827 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature